Robert Ho - 03 Aug 2021 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)

Role
Chief Financial Officer
Signature
/s/ Kris McGrew, Attorney-in-Fact for Robert Ho
Issuer symbol
NGNE
Transactions as of
03 Aug 2021
Net transactions value
$0
Form type
4
Filing time
05 Aug 2021, 16:14:59 UTC
Next filing
02 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Stock Option (Right to Buy) Award $0 +190,000 $0.000000 190,000 03 Aug 2021 Common Stock 190,000 $6.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/4 of the total shares on August 3, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.